Patient characteristics
| . | Overall . | t(4;14)− . | t(4;14)+ . |
|---|---|---|---|
| N (%) | 208 | 177 (85%) | 31 (15%) |
| Age, y, median (range) | 67 (30-89) | 67 (30-89) | 65 (41-87) |
| Sex, F/M | 67/141 | 57/120 | 10/21 |
| Durie-Salmon stage, no. (%) | |||
| I | 24 (12) | 18 (10) | 6 (19) |
| II | 32 (15) | 26 (15) | 6 (19) |
| III | 152 (73) | 133 (75) | 19 (61) |
| B (sCr greater than 2 mg/dL) | 38/202 (19) | 34/171 (20) | 4/31 (13) |
| Clinical isotype, no. (%) | |||
| IgG | 119 (57) | 100 (56) | 19 (61) |
| IgA | 44 (21) | 35 (20) | 9 (29) |
| Light chain | 34 (16) | 32 (18) | 2 (6) |
| Other/unspecified | 11 (5) | 10 (6) | 1 (3) |
| Lytic bone disease, (%) | 136/205 (66) | 117/176 (66) | 19/29 (66) |
| Calcium level greater than 12 mg/dL, (%) | 18/198 (9) | 16/168 (10) | 2/30 (6) |
| Hb level less than 8.5 g/dL, (%) | 37/206 (18) | 32/175 (18) | 5/31 (16) |
| Elevated LDH level, (%) | 24/152 (16) | 21/127 (17) | 3/25 (12) |
| β2-microglobin level greater than 3 mg/L, (%) | 111/155 (72) | 96/134 (72) | 15/21 (71) |
| Urine protein level greater than 4 g/day, (%) | 31/119 (26) | 24/104 (23) | 7/15 (47) |
| Primary systemic therapy, no. (%) | |||
| None | 14 (7) | 10 (6) | 4 (13) |
| Chemotherapy | 126 (61) | 108 (61) | 18 (58) |
| Autologous SCT | 63 (30) | 55 (31) | 8 (26) |
| Allogeneic SCT | 1 (0.5) | 1 (0.6) | 0 |
| Unspecified | 4 (2) | 3 (2) | 1 (3) |
| Patients decreased, no. (%) | 99 (48) | 80 (45) | 19 (61) |
| Survivor follow-up, y, median (range) | 2.2 (0-12.9) | 2.4 (0-12.9) | 1.2 (0-3.5) |
| . | Overall . | t(4;14)− . | t(4;14)+ . |
|---|---|---|---|
| N (%) | 208 | 177 (85%) | 31 (15%) |
| Age, y, median (range) | 67 (30-89) | 67 (30-89) | 65 (41-87) |
| Sex, F/M | 67/141 | 57/120 | 10/21 |
| Durie-Salmon stage, no. (%) | |||
| I | 24 (12) | 18 (10) | 6 (19) |
| II | 32 (15) | 26 (15) | 6 (19) |
| III | 152 (73) | 133 (75) | 19 (61) |
| B (sCr greater than 2 mg/dL) | 38/202 (19) | 34/171 (20) | 4/31 (13) |
| Clinical isotype, no. (%) | |||
| IgG | 119 (57) | 100 (56) | 19 (61) |
| IgA | 44 (21) | 35 (20) | 9 (29) |
| Light chain | 34 (16) | 32 (18) | 2 (6) |
| Other/unspecified | 11 (5) | 10 (6) | 1 (3) |
| Lytic bone disease, (%) | 136/205 (66) | 117/176 (66) | 19/29 (66) |
| Calcium level greater than 12 mg/dL, (%) | 18/198 (9) | 16/168 (10) | 2/30 (6) |
| Hb level less than 8.5 g/dL, (%) | 37/206 (18) | 32/175 (18) | 5/31 (16) |
| Elevated LDH level, (%) | 24/152 (16) | 21/127 (17) | 3/25 (12) |
| β2-microglobin level greater than 3 mg/L, (%) | 111/155 (72) | 96/134 (72) | 15/21 (71) |
| Urine protein level greater than 4 g/day, (%) | 31/119 (26) | 24/104 (23) | 7/15 (47) |
| Primary systemic therapy, no. (%) | |||
| None | 14 (7) | 10 (6) | 4 (13) |
| Chemotherapy | 126 (61) | 108 (61) | 18 (58) |
| Autologous SCT | 63 (30) | 55 (31) | 8 (26) |
| Allogeneic SCT | 1 (0.5) | 1 (0.6) | 0 |
| Unspecified | 4 (2) | 3 (2) | 1 (3) |
| Patients decreased, no. (%) | 99 (48) | 80 (45) | 19 (61) |
| Survivor follow-up, y, median (range) | 2.2 (0-12.9) | 2.4 (0-12.9) | 1.2 (0-3.5) |
SCT indicates stem cell transplantation; sCr, serum creatinine; and Hb, hemoglobin.